drugset / Press release
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
2026-07-06 · Aurinia Pharmaceuticals Inc. · original auriniapharma.com ↗
— Multitarget Approach Has Potential to Further Improve Outcomes in This Disease Characterized by Continued Unmet Need —
The release as fetched from its publisher. auriniapharma.com ↗